SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism

Summary

Locomotor, transport and information functions in human body systems are carried out by active media in autowave regimes! Any living organism is a (micro-macro-mega) hierarchy of autowave subsystems-an ensemble of loosely coupled subsystems of a simpler structure. From the highest levels of the hierarchy, Autowave Codes-Signals arrive, which determine the transitions of subsystems from one autowave regime to another Autowave interaction (of Complex Coherent Action). Autowave interaction is a process associated with the evolution and interaction of spatial and wave structures in the active media of the organism.

Chaos in organism functioning tells about health. Periodicity - Autowave reverberator may presage a disease - Autism Spectrum Disorder; Chaotic nature of oscillations in active media of physiological systems is more optimal for their vital functions than periodic one. Firstly, systems that function in chaotic regimes, can re-arrange themselves faster and easier in case of change of environmental conditions, i.e. the so called adaptive control is more easily implemented in them. Secondly, "spreading" of oscillations strength along comparatively wide frequency band takes place in chaotic regime.

When an organism is young and healthy, physiological systems show the elements of chaotic behavior, i.e. irregularity and chaotic dynamics are the extremely important characteristics of health. Decrease in changeability and appearance of stable periodicity of Autowave reverberator are often connected with Autism.

The main purpose is to study brain plasticity (the changes that occur in the brain through Autowave reverberator) in children with autism. Research suggests that during development, the brains of children may change in response to their Autowave reverberator differently than the brains of typically developing individuals. Investigators want to understand why and how this difference may contribute to the symptoms of autism spectrum disorder (ASD). In this study, the investigators will be examining the effects of non-invasive neuromodulation SQUED™ series 28.1 home-use for Treatment of Autowave reverberator of Autism.

Integrative Team World Organization of Medical Synergetics (WOMS) - collaborations between physicians and researchers with expertise in biostatistics, physics, mathematics, engineering, and computer science.

Conditions

• Autistic Disorder
• Autism Spectrum Disorder
• Child Development Disorders, Pervasive
• Neurodevelopmental Disorders
• Mental Disorders
• Asperger's Syndrome
• Neurobehavioral Manifestations
• Nervous System Diseases

Interventions

DEVICE

SQUED™ series 28.1 home-use

Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy. Some autowaves have the properties of quasi-particles!

Sponsors & Collaborators

• Clinic of Synergetics, Department of Neurology/Neuropsychology WOMS

  collaborator UNKNOWN

• Institute of Medical Synergetics, Department of Cognitive Neurology WOMS

  collaborator UNKNOWN

• Laboratory of Neurocomputational Active Media WOMS

  collaborator UNKNOWN

• SQUED, Inc., USA

  collaborator UNKNOWN

• Center of Synergetics, Universität Stuttgart, Germany

  collaborator UNKNOWN

• Ivan Franko National University of Lviv, Ukraine

  collaborator UNKNOWN

• Danylo Halytsky Lviv National Medical University

  collaborator OTHER

• World Organization of Medical Synergetics

  collaborator OTHER

• World Autism Center, American Federation of Medical Synergetics

  collaborator UNKNOWN

• American Federation of Medical Synergetics

  lead OTHER

Principal Investigators

• Yuliya Yaroshuk, M.D.s. Ph.D. · World Autism Center, American Federation of Medical Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology WOMS

• Yuriy Fihol, M.D.s. Ph.D. · Clinic of Synergetics, Department of Neurology; Cognitive Neurology/Neuropsychology of the World Organization of Medical Synergetics

Eligibility

Min Age

1 Month

Max Age

21 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-09-26

Primary Completion

2022-09-30

Completion

2027-12-31

FDA Device

Yes

Countries

• United States
• Ukraine

Study Locations